Cyclin E in human cancers.
Regulators of the cell cycle such as cyclin E play an important part in neoplasia. The cyclin E protein forms a partnership with a specific protein kinase. This complex phosphorylates key substrates to initiate DNA synthesis. Cyclin-dependent kinase inhibitors (CKIs) are able to suppress the activity of cyclin E. Various substances (including proteins produced by oncogenic viruses) affect cyclin E directly or indirectly through an interaction with CKIs. These interactions are important in elucidating the mechanisms of neoplasia. They may also provide prognostic information in a wide range of common cancers. Cyclin E may even be a target for treatment of cancers in the future.
Donnellan
R
R
Department of Pathology, University of Natal Medical School, Durban, South Africa. donnellanr@med.und.ac.za
Chetty
R
R
D001943:Breast Neoplasms / Q000209:etiology; D002453:Cell Cycle / Q000502:physiology; D019927:Cyclin E / Q000235:genetics / Q000502:physiology*; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000209:etiology; D015870:Gene Expression; D019337:Hematologic Neoplasms / Q000209:etiology; D006801:Humans; D008954:Models, Biological; D009369:Neoplasms / Q000209:etiology*; D009858:Oncogenic Viruses / Q000472:pathogenicity; D016160:Retinoblastoma Protein / Q000502:physiology; D016196:S Phase / Q000502:physiology; D014565:Urogenital Neoplasms / Q000209:etiology
D019927:Cyclin E; D016160:Retinoblastoma Protein; D018844:Cyclin-Dependent Kinases